SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Forward Therapeutics Receives FDA IND Clearance for Phase 2 FT2109 Study

Forward Therapeutics says the FDA cleared its investigational new drug application to begin a Phase 2 study of FT2109 in psoriatic arthritis.

Related stories